<DOC>
	<DOCNO>NCT00425256</DOCNO>
	<brief_summary>This 8 week home study design explore efficacy endpoint evaluate safety intranasal Bremelanotide woman Female Sexual Arousal Disorder . Efficacy assess vs. parallel placebo group .</brief_summary>
	<brief_title>Evaluate Safety Efficacy Bremelanotide Women With Female Sexual Arousal Disorder ( FSAD )</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>alpha-MSH</mesh_term>
	<criteria>Post menopausal general good health In stable relationship male partner least 6 month Willing attempt sexual activity week partner</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>